Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Prostatic Neoplasms 13Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroblastoma 4Glioblastoma 4Colorectal Neoplasms 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Ganglioneuroblastoma 3Disease 3Carcinoma, Hepatocellular 3Carcinoma 3Ureteral Neoplasms 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2

Interventions

Radiotherapy 10Vincristine 9Dactinomycin 8Cyclophosphamide 8Radiation 6Ifosfamide 6Doxorubicin 5Irinotecan 4Filgrastim 4Etoposide 4Vinorelbine 3sargramostim 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trofosfamide 1trioctyl phosphine oxide 1temsirolimus 1pegfilgrastim 1etoposide phosphate 1X-Rays 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sirolimus 1Sentinel Lymph Node Biopsy 1Phantoms, Imaging 1Idarubicin 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Rhabdomyosarcoma × Magnetic Resonance Spectroscopy × Clear all
NCT04994132 2026-05-05

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Active not recruiting
118 enrolled
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡